Osmium Compound Could Help Ovarian Cancer Patients Who Are Resistant to Platinum Therapies

Osmium Compound Could Help Ovarian Cancer Patients Who Are Resistant to Platinum Therapies
An organometallic compound called Organo-Osmium FY26 may be a promising therapy for ovarian cancer, according to a study. Researchers said FY26, which includes the metal osmium, may be able to kill ovarian cancer cells up to 50 times better than current platinum-based therapies. The researchers noted that FY26 uses a different mechanism than platinum therapies to kill ovarian cancer cells. This suggests that it might be used in patients who no longer respond to platinum-based chemotherapies. The study, "Synchrotron X-Ray Fluorescence Nanoprobe Reveals Target Sites for Organo-Osmium Complex in Human Ovarian Cancer Cells,” was published in the journal Chemistry - A European Journal. An organometallic compound contains bonds between the carbon atom of an organic compound and a metal. Several of these transition metal molecules can fight cancer, but how they identify and kill cancer cells has remained elusive. Researchers used a fluorescent light probe called a synchrotron X-ray fluorescence nanoprobe (SXRFN) to see how Organo-Osmium FY26 works inside ovarian cancer cells. "These kinds of experiments are normally performed using bigger doses than what would be done in real life or on a coarse scale that does not provide a clear picture of the processes that take place,” Peter Cloetens, a co-senior author of the study, said in a news release. With nano-imaging, "by combining a very tight focus and high flux, we could get a real picture of where the drug goes in a single cell using real-life p
Subscribe or to access all post and page content.